RAPAMYCIN |
SIROLIMUS |
L04AA10 |
RAPAMUNE |
SM-88 COMPONENT SIROLIMUS |
AY-22989 |
WY-090217 |
NSC-226080 |
(-)-RAPAMYCIN |
drugbank:00877 |
chembl:CHEMBL413 |
pubchem.compound:5284616 |
rxcui:35302 |
chemidplus:53123-88-9 |
Notes | rapalogue |
Drug Class | Kinase Inhibitors |
Drug Indications | for treatment of wet age-related macular degeneration |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | immunosuppressant |
Drug Categories | hyperglycemia-associated agents |
Drug Class | immunosuppressive agents |
Year of Approval | 2007 |
Drug Categories | agents causing angioedema |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 cyp3a5 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a7 substrates |
Drug Categories | cytochrome p-450 cyp3a7 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | decreased immunologic activity |
Drug Categories | kinase inhibitor |
Drug Categories | mtor inhibitor immunosuppressant |
Drug Categories | mtor inhibitors |
Drug Categories | narrow therapeutic index drugs |
Drug Categories | oatp1b1/slco1b1 inhibitors |
Drug Categories | ophthalmologicals |
Drug Categories | p-glycoprotein inducers |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | p-glycoprotein substrates with narrow therapeutic index |
Drug Categories | protein kinase inhibitors |
Drug Categories | sensory organs |
Drug Categories | sirolimus and prodrugs |
other/unknown |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | FK506-binding protein 1A inhibitor |
Details of the Assay for Interaction | Measuring ability to inhibit the proteins rotamase activity |
inhibitor (inhibitory) |
Drug family | MTOR inhibitor |
Alteration | MTOR:L1460P,S2215Y,R2505P |
Trial Name | LCP-Siro, sirolimus |
other/unknown |
Trial Name | LCP-Siro, sirolimus |
Novel drug target | Established target |
n/a |
Drug family | MTOR inhibitor |
Alteration | PTEN:del |
Alteration | PTEN:. |
SIROLIMUS | DrugBank Drug Name |
53123-88-9 | CAS Number |
Gd-sirolimus | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
AY22989 | Development Name |
SILA9268A | Development Name |
WY-090217 | Development Name |
Drug Class | Kinase Inhibitors |
Notes | rapalogue |
SIROLIMUS | Primary Drug Name |
Year of Approval | 2007 |
Drug Class | immunosuppressive agents |
Drug Indications | immunosuppressant |
Drug Class | Small Molecule |
FDA Approval | approved |
CHEMBL413 | ChEMBL Drug ID |
C1212 | NCI drug code |
C1212 | NCI drug code |
SIROLIMUS | Primary Drug Name |
SIROLIMUS | Drug Generic Name |
RAPAMUNE | Drug Trade Name |
D03LJR | TTD Drug ID |
SIROLIMUS | GuideToPharmacology Ligand Name |
D0T6DK | TTD Drug ID |